v1

Change Notification for the UK Blood Transfusion Services

Date of Issue: 26 November 2024

Implementation: to be determined by each Service

No. 47 - 2024

Topical Anti-Androgens

This notification includes the following changes:

| | BM-DSG Bone Marrow & Peripheral Blood Stem Cell | CB-DSG | GDRI Geographical Disease Risk Index | TD-DSG Tissue - Deceased Donors | TL-DSG Tissue - Live Donors | WB-DSG Whole Blood & Components | Red Book Guidelines for the BTS in the UK |
|-------------------|--|--------|---|--|--------------------------------------|---------------------------------------|---|
| 1. Anti-Androgens | | | | | | | |

eght.

Dr Angus Wells Chair of Standing Advisory Committee on Care & Selection of Donors (SACCSD)

Sepons.

Dr Stephen Thomas Professional Director of JPAC

| Changes are indicated using the key below. This formatting will not appear in the final entry. | | | | | |
|--|-----------------|-------------------------|--|--|--|
| original text | «inserted text» | deleted text | | | |
| | | | | | |
| transfusionguidelines.org Page 1 of 2 | | JPACOffice@nhsbt.nhs.uk | | | |

v1

1. Changes apply to the Whole Blood and Components DSG

Anti-Androgens

(revised entry)

| Includes | Bicalutamide (Casodex®), cyproterone acetate (Androcur®, Cyprostat®), dutasteride (Avodart®), finasteride (Propecia®, Proscar®) and flutamide (Drogenil®). |
|------------------------|---|
| Obligatory | Must not donate if: |
| Obligatory | |
| | a) Dutasteride (Avodart®) taken in the last six months. |
| | b) Finasteride (Propecia®, Proscar®) taken in the last four weeks. |
| | |
| | c) Bicalutamide (Casodex®), cyproterone acetate (Androcur®, Cyprostat®) or flutamide (Drogenil®) has been taken for a malignant condition. |
| Discretionary | «1.» Donors taking cyproterone acetate for non-malignant conditions, if not affected by the <u>Blood Safety Entry</u> , accept. |
| | «2. Donors using topical anti-androgen treatments for alopecia, including male pattern baldness, accept.» |
| See if Relevant | Acne |
| | Blood Safety Entry |
| | Hair Removal |
| | |
| | Malignancy |
| | Prostate Problems |
| Additional Information | Dutasteride and finasteride can cause abnormal development of the sexual organs of a male baby within the womb. As it is not possible to know if an individual donation may be transfused to a pregnant woman whose baby may be at risk, donations cannot be taken from people who may have one of these drugs in their blood. They remain in the blood even after treatment has stopped. |
| | Cyproterone acetate (particularly in the form of Androcur®) may be used to treat male hypersexuality. In such cases a sensitive exploration of any relevant issues dealt with by the <u>Blood Safety Entry</u> should be undertaken. |
| Reason for Change | «A discretion to accept donors using topical anti-androgens has been added.» |
| | This is a new entry. |
| Donor Information | If you wish to obtain more information regarding a personal medical issue, please contact your <u>National Help Line</u> . |
| | Please do not contact this web site for personal medical queries, as we are not in a position to provide individual answers. |